Our recently created Chau Eagle Global IP had a successful exhibition at the BIP Asia 2017.

Chau Eagle Global IP is a merged practice between two top tier IP boutiques, Eagle IP in HK and F. Chau & Associates in New York. F. Chau & Associates, has been ranked No. 1 in New York (and No. 6 in the United States) for patent quality in consumer electronics by Ocean Tomo.

Our Past Events

Jennifer Che has been Recognized in IAM Strategy 300 Global Leaders 2026

26 November 2025

Jennifer Che has been Recognized as IAM Global Leaders 2026

4 November 2025

Eagle IP is Coming to San Francisco and Washington DC!

15 October 2025

Jennifer Che has been listed on the IAM Strategy 300

15 August 2025

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

3 July 2025

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

13 June 2025

Recommended Insights

Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent

4 February 2025
The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]
Read more >

AI, Big Data, and Blockchain - CNIPA seeks public comment on draft patent examination guidelines

21 November 2019
Exciting new changes continue to happen with the Chinese Patent Office (CNIPA). On November 12, 2019, the CNIPA published a new set of amendments to Part II Chapter 9 of the Patent Examination Guidelines (“Draft”) and requested public comment by December 11, 2019. In summary, the new guidelines clarify how emerging technologies involving artificial intelligence, […]
Read more >

Diagnostic Claims in China

9 January 2020
The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]
Read more >

How will Civil Cases Work under the Patent Linkage Provision in the New Chinese Patent Law?

20 November 2020
The Supreme People’s Court has just issued draft regulations for comment regarding how new Article 76 will work in conjunction with civil procedure law. The period to submit comments ends December 14, 2020, and the final version will come into force June 1, 2021, together with the new Chinese Patent Law. The Backdrop: New Chinese […]
Read more >
Top crossarrow-right